Navigation Links
Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
Date:4/18/2011

HAYWARD, Calif., April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that enrollment in the Phase 3 VISTA-16 study of varespladib in Acute Coronary Syndromes (ACS) will continue based on the positive outcome of an interim biomarker analysis and review of available patient safety data.

An independent statistician completed an analysis of various biomarkers of cardiovascular risk and determined that treatment with once-daily varespladib met the pre-specified criteria for the study to proceed.  The analysis required patients on varespladib to demonstrate pre-defined treatment effects versus placebo at relevant time points on a collection of biomarkers including:  secretory phospholipase A2 (sPLA2), low density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), interleukin-6 (IL-6), and a composite responder endpoint defined as patients achieving LDL-C less than 70 mg/dL and CRP below 1.0 mg/L.  

In parallel with the biomarker analysis, the VISTA-16 independent Data Safety and Monitoring Board (DSMB) completed a review of the available safety database including all reported adverse events and serious adverse events and recommended the continuation of the VISTA-16 clinical study without modification.  This represents the third meeting of DSMB since the start of the study.

"We continue to believe that positive changes in patient biomarkers similar to changes seen in the FRANCIS Phase 2 clinical study will correlate to a reduction in major adverse cardiovascular events in patients treated with varespladib for 16 weeks," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "We are hopeful this approach will eventually prove that rapid and safe reduction of inflammation
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
2. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
3. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
4. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
5. Anthera Announces Update Call Regarding Vial Problems
6. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
7. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
8. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
9. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
10. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
11. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... New Zealand , July 28, 2014 /PRNewswire/ ... in Sweden has validated ... multiple vendor platforms and has associated volumetrically assessed ... in Cancer Epidemiology, Biomarkers & Prevention ... mammographic density: a tool for widespread breast cancer ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
... PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced ... for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced ... in vivo antitumor activity and a favorable safety ... in clinical development. The trials will be performed ...
... Feb. 7, 2011 Pharmasset, Inc. (Nasdaq: ... discovering, developing, and commercializing novel drugs to treat viral ... the quarter ended December 31, 2010. ... ended December 31, 2010 compared to $0.3 million for ...
Cached Medicine Technology:PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 3Pharmasset Reports Fiscal First Quarter 2011 Financial Results 4Pharmasset Reports Fiscal First Quarter 2011 Financial Results 5Pharmasset Reports Fiscal First Quarter 2011 Financial Results 6
(Date:7/28/2014)... July 29, 2014 “China Surgical ... data on the China Surgical Generators market. The ... volume (in units) and average prices (in US ... Generators, Ultrasonic Generators and Argon Plasma Coagulation Generators. ... distribution shares data for each of these market ...
(Date:7/28/2014)... Heights, MI (PRWEB) July 28, 2014 ... UHY, introduces the latest edition of UHY International Business ... provided by our members, on the most current business ... around the world. Issue 29 covers the following topics:, ... growth: Which industry sectors will thrive over the next ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... July 28, 2014 Thousands of DePuy ... behalf of individuals who were allegedly injured by a ... to move forward in U.S. District Court, Northern District ... Order issued on July 18, 2014, U.S. District Judge ... by the Plaintiffs’ Steering Committee that sought the deposition ...
(Date:7/28/2014)... Ticket Down is a dependable source for cheap ... the Sun Life Stadium in early September. The decades ... has is one that has continues to go on. With ... a consistent basis. The rivalry between South America nations, ... 2014 World Cup. To the delight of soccer aficionados ...
Breaking Medicine News(10 mins):Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3
... researcher at The University of Texas Health Center at ... of the blood-clotting process works. Once the process// is ... it, thus preventing excessive bleeding or blood clotting. The ... published in the Aug. 11, 2006, edition of the ...
... tuberculosis, precautionary letters have been sent to 500 people ... the// disease. The condition of the patient suffering ... ,The patient was diagnosed with active form ... diseases unit at Aberdeen Royal Infirmary from Aberdeen's Woodend ...
... who advice patients to give up smoking may be more ... according to a new study in the July-August 2006// Nursing ... recognized as central to global efforts to reduce the detrimental ... Nursing Research editor and professor of nursing at the University ...
... An MRI-guided breast biopsy successfully removed the breast lesion ... slices of the lesion, according to radiologists. "Contrast-enhanced// MRI ... with lesions that cannot be detected with other techniques," ... the University of Texas M.D. Anderson Cancer Center in ...
... as a hazard of aging, but researchers actually do ... aging// or not. Researchers at the Salk Institute for ... conducted a study that proves it is aging that ... beta amyloid aggregates accumulate when aging impedes two molecular ...
... Dr. Morey Haymond, chief of paediatric endocrinology at Texas Children's ... tale signs of diabetes in children. , ,Children ... a bit more independent, hence parents many not be able ... 2 diabetes is more an affliction with the obese and ...
Cached Medicine News:Health News:Scientist Discovers Crucial Part of Blood-Clotting Process 2Health News:Nurses Can Play Big Role In Helping Patients Quit Smoking 2Health News:MRI-guided Breast Biopsy Pronounced a Success 2Health News:Aging Critical For Alzheimer's Disease 2Health News:Aging Critical For Alzheimer's Disease 3
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... Heavy Duty is a pressure relief mattress overlay ... specifically to the BariKare® Bed., ,INDICATIONS , ... lbs., Large patients at risk or suffering from ... mattress that would benefit from a pressure relief ...
... is a healthcare bed system which helps ... the home care setting, ,INDICATIONS: ,Patients ... of 2) ,Healthcare frame accommodating one ... selected, ,CONTRAINDICATIONS: ,Total weight in excess ...
Medicine Products: